← All trials
NCT04780672
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2021
- Primary completion
- May 31, 2022
- Completion date
- Sep 30, 2022
- First posted
- Mar 3, 2021
- Last posted
- Oct 11, 2021
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- VamstarLead sponsor
- Yaroslavl Regional Clinical Hospital for Military VeteransOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Moscow State UniversityOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Regional State Healthcare Institution Smolensk Regional Clinical HospitalOverall official - principal investigator
- Republican Clinical Infectious Diseases Hospital named after professor AgafonovOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.